20 articles
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
A structured neuroplasticity-based program improved functional performance and emotional well-being in community-dwelling older adults with dementia.
Small pilot study examined psilocybin's effects on brain circuits and emotion processing in healthy adults to understand abuse potential.
Personalized treatment approach targeting multiple causes of cognitive decline outperformed standard care in 9-month trial.
A Columbia University trial tests whether a hip hop-based dementia education program builds lasting literacy and reduces stigma in children and families.
German researchers test whether digital environmental enrichment can boost mental and physical wellbeing in seniors through telehealth.
Clinical trial explores whether resetting gut microbiome through fecal transplants can slow Parkinson's progression and reduce symptoms.
A completed Phase 1 trial compared the abuse liability of rapastinel versus ketamine in recreational polydrug users, with implications for safer depression treatment.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
Novel movement program combining Eastern and Western exercises may help maintain independence and cognitive function in dementia patients.
A completed longitudinal study tracks brain structure, function, and behavior in healthy infants across the first year of life.
Small pilot study tests multicomponent behavioral program to reduce cognitive decline risk in underserved rural populations.
Small study reveals BDNF genetic variant could influence exercise's cognitive and cardiovascular benefits in healthy men.
Duke University study tests whether targeted brain stimulation can reverse age-related cognitive decline and improve working memory.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
Probucol, a discontinued cholesterol medication, may boost brain-protective proteins in older adults at risk for dementia.
Clinical trial explores how targeted light treatment could restore circadian rhythms and improve brain function in mild cognitive impairment.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
Applied Cognition tests a wearable device that tracks glymphatic function overnight, comparing it to MRI, EEG, and blood biomarkers.
12-week intensive cognitive training program tested in 76 adults with early memory problems to assess brain function improvements.
